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1. Introduction
Delirium is categorized in the cognitive disorders, characterized by acute onset, global im‐
pairment in cognitive, emotional, mental, and behavioral functioning, fluctuating level of
consciousness, attention impairment, decreased or increased psychomotor activity and the
disturbance of sleep-wake cycle. Emotional and behavioral abnormalities are common pre‐
sented with some neurological manifestations, e.g., tremor, asterixis, nystagmus, incoordi‐
nation, urinary incontinence.
Delirium is a behavioral disturbance and serious complication commonly found in consulta‐
tion-liaison psychiatry. Its prevalence and incidence rates are varied, possibly depend on se‐
verity of illness, patient population, the method of assessment and the diagnostic criteria.
Prevalence of delirium ranges from 10% to 30% and its incidence is between 3% and 29% for
patients admitted in general hospitals (Siddiqi et al., 2006, Maneeton et al., 2007a, Praditsu‐
wan et al., 2012). High prevalence and incidence are noted in elderly and severely ill pa‐
tients. For instance, the prevalence of delirium in elderly and ICU patients are up to 40%
and 80%, respectively (Bledowski and Trutia, 2012, Praditsuwan et al., 2012).
An occurrence of delirium is associated with miserable clinical outcomes. It often increases
morbidity, mortality, length of hospitalization, institutionalization, and poor functional out‐
come (Siddiqi et al., 2006, Cole et al., 2009, Fong et al., 2012). The mortality rate is higher in
patients with hypoactive subtype of delirium (Yang et al., 2009).
Delirium is often under recognized by health professionals. There are many faces for the
clinical presentation of delirium. It can be caused by a variety of etiology. To prevent and
minimize the consequences of delirium, physician should prompt intervenes for this condi‐
tion (Attard et al., 2008).
© 2013 Maneeton and Maneeton; licensee InTech. This is an open access article distributed under the terms
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This chapter aims to summarize current strategies for managing and preventing delirium
caused by a variety of etiology, except substance withdrawal delirium. In addition, etiolo‐
gies, clinical manifestations and risk factors are also addressed.
2. Definition
According to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revi‐
sion (DSM-IV-TR), delirium due to a general medical condition is defined by four criteria: a.
disturbance of consciousness (i.e., reduced clarity of awareness of the environment) with re‐
duced ability to focus, sustain, or shift attention; b. a change in cognition (such as memory
deficit, disorientation, language disturbance) or the development of a perceptual disturb‐
ance that is not better accounted for by a preexisting, established, or evolving dementia; c.
the disturbance develops over a short period of time (usually hours to days) and tends to
fluctuate during the course of the day; d. there is evidence from the history, physical exami‐
nation, or laboratory findings that the disturbance is caused by the direct physiological con‐
sequences of a general medical condition(American Psychiatric Association, 2005).
For the ICD-10, delirium not induced by alcohol and other psychoactive substances is de‐
fined as an etiologically nonspecific organic cerebral syndrome characterized by concurrent
disturbances of consciousness and attention, perception, thinking, memory, psychomotor
behavior, emotion, and the sleep-wake schedule. The duration is variable, and the degree of
severity ranges from mild to very severe (World Health Organization, 1993).
3. Clinical manifestation
The hallmark of delirium is rapid and fluctuated disturbance of consciousness, orientation
and global cognitive functioning.
3.1. Prodromal phase
Prodromal symptoms may be observed for hours to a few days in some patients. These
symptoms include restlessness, anxiety, irritability, hypervigilance, drowsiness, transient
hallucination, nightmare and etc. Because these symptoms are not specific for delirium, they
may be overlooked by health care providers.
3.2. Fluctuating course
Most patients have rapidly changes of emotion and cognition. The diurnal fluctuation is
common. Because the patient’s condition is usually worse at night time, this clinical feature
may be called "sundowner's syndrome". During thi speriod of time, delusion, hallucination,
depression, irritability and anxiety are frequently prominent.
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3.3. Disorientation
Most patients are disoriented to time, place and/or person.
3.4. Sleep-wake cycle abnormality
Sleep-wake disturbance is usually noted in delirium. The patients may be sleepy during the
day and stay awake at night. The sleep pattern is characterized by brief and fragmented pe‐
riods of sleeping time.
3.5. Psychomotor disturbance
Arousal disturbance is common and usually related to the abnormality of reticular activat‐
ing system. Currently, psychomotor behavior of delirium is categorized into four subtypes,
including normal, hypoactive, hyperactive, and mixed (Yang et al., 2009). Hyperactive delir‐
ium is characterized by agitation, restlessness and hypervigilance. Lethargy, somnolence,
apathy, depression, catatonia and quiet confusion are common for hypoactive delirium. For
the mixed subtype, it manifests both psychomotor hypoactivity and hyperactivity.
3.6. Perceptual disturbance
Because most delirious patients cannot discriminate and integrate the sensory stimuli
around them, illusions and hallucinations are common in this population. The patients are
easily frustrated or distracted when they encounter new information.
3.7. Dysfunction of higher cortical function
Although the DSM IV-TR does not include language difficulties, most patients have speech
abnormality, such as rambling, irrelevancy and incoherent. Impairment of memory, espe‐
cially the short-termone, can be found in most patients. The impaired short-term memory
may be explained by the loss of concentration, perceptual disturbance, and/or malfunction
of the hippocampus. Since delirium is a global cerebral dysfunction, higher cortical dysfunc‐
tion such as dysphasia, dyspraxia, dysgraphia, is also common. In addition, the patients
may have other neurological signs, e.g., tremor, asterixis, incoordination and urinary incon‐
tinence.
4. Predisposing and risk factors
Individuals are differently susceptible to delirium. Despite the exposing to the same causa‐
tive factor, individuals are not equally prone to develop delirium. Predisposing and risk fac‐
tors appear to play a role in the susceptibility to delirium. There have been numerous
studies on predisposing and risk factors of delirium. For instance, Inouye and Charpentier
(1996) demonstrated the five independent precipitating factors for delirium, including use of
physical restraints, malnutrition, more than three medications taken, use of bladder catheter
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and any iatrogenic event. Recently, risk factors for delirium have been established in four
domains, including patient characteristics, chronic pathology, acute illness, and environ‐
mental factors (Van Rompaey et al., 2009). Another study in elderly patients receiving hip
surgery found that early symptoms of memory impairments, incoherence, disorientation
and underlying somatic illness were predictors of delirium (de Jonghe et al., 2007).
In general, the common predisposing and risk factors for delirium that have been recog‐
nized are age of 60 years or over, brain damage (e.g., stroke, brain injury), chronic organic
brain syndrome (e.g., dementia of Alzheimer type), postoperative patients, history of deliri‐
um, diabetes, malignancy, sensory impairment (e.g., blindness, deafness) and HIV infection.
5. Etiology
Common causes of delirium include central nervous system (CNS) diseases, systemic dis‐
eases, intoxication or withdrawal from substance and toxic agent. Most delirious patients of‐
ten encounter with multiple causes.
5.1. Medications
The use of medication is one of the most common causes of delirium. Medications that have
been identified are antibiotics, antidepressants, antihistamines, anticholinergic agents, anti‐
parkinson agents, antipsychotic medications, antineoplastics, anticonvulsants, antitubercu‐
losis agents, cardiac drugs, diuretics, non-steroidal anti-inflammatory drugs, L-dopa,
lithium, opiates, sedative-hypnotics, steroids, sympathomimetic agents. It has been found
that the administration of three medications or more is a risk factor for delirium. Because
elderly patients tend to take multiple medications, they are a population at particular risk
for delirium (Inouye, 2004, Clegg and Young, 2011, Catic, 2011).
5.2. Neurological causes
Delirium is a state of global cerebral dysfunction. Therefore, any pathology in the CNS may
cause this syndrome. Common neurological contributors for delirium consist of head injury,
stroke, hypertensive encephalopathy, intracranial neoplasm and epilepsy (Ramirez-Bermu‐
dez et al., 2006, Martin, 2012).
5.3. Infection
Infection, in particular sepsis, can be a cause of delirium (Rahkonen et al., 2000, Srinonpra‐
sert et al., 2011, Zampieri et al., 2011). Other infectious diseases commonly found, including
CNS infection (Ramirez-Bermudez et al., 2006); meningitis, encephalitis, brain abscess, neu‐
rosyphilis, HIV encephalopathy and other systemic infection (Warshaw and Tanzer, 1993,
Eriksson et al., 2011, van Gool et al., 2010).
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5.4. Metabolic disorders
Metabolic disturbances are frequently associated with delirium (Khurana et al., 2011, Grover
et al., 2012). Common metabolic abnormalities consist of hepatic encephalopathy, hypo- or
hyperglycemia, hypoxia, hypo- or hypernatremia, hypo- orhypercalcemia, hypo- orhyper‐
magnesemia, acidosis, uremia and metabolic acidosis (Aldemir et al., 2001, Khurana et al.,
2011).
5.5. Vitamin deficiency
Vitamin deficiency, such as thiamine, B12, nicotinic acid, folic acid, is a common factor con‐
tributing to the development of delirium (Kane et al., 1993, O'Keeffe et al., 1994, Harrington
et al., 2011).
5.6. Endocrine abnormalities
Several lines of evidence suggest that endocrine disturbances may be a cause of delirium
(Olsson, 1999, Grover et al., 2012). Common abnormalities include hypo- or hyperthyroid‐
ism, hypo- or hyperparathyroidism, Cushing's syndrome, Addison's disease, pheochromo‐
cytoma and hypopituitary diseases (Olsson, 1999, Maldonado, 2008a).
5.7. Withdrawal syndrome
The withdrawal of some drugs or substances could precipitate the phenomena of delirium.
Those possible causative agents are alcohol, benzodiazepines, barbiturates, other sedatives
and hypnotics (Saitz, 1998, Trevisan et al., 1998, Maldonado, 2008a, Yu et al., 2012).
5.8. Substance abuse
Numerous substances, for instance methamphetamine, cocaine, hallucinogens, inhalants,
opioids and bath salts may be a cause of delirium (Nakatani and Hara, 1998, Maldonado,
2008a, Fadel and Serra, 2009, Kasick et al., 2012 Burapakajornpong et al., 2012).
5.9. Toxin exposure
Toxin exposure is also a significant contributor in the development of delirium. Example
toxic agents are heavy metals and toxins (Maldonado, 2008a).
6. Pathophysiology
Since there have been only a few studies on the mechanism of delirium, its pathophysiology
are still poorly understood. However, some recent findings suggest several mechanisms
possibly related to the development of delirium, including abnormality in neurotransmit‐
ters, inflammatory response, the blood-brain barrier permeability, cerebral oxidative metab‐
olism and the hypothalamic-pituitary adrenal axis (Flacker and Lipsitz, 1999, van der Mast,
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1998, Gunther et al., 2008, Marcantonio et al., 2006). However, the heterogeneity of the delir‐
ium syndrome and the populations are the major challenges. The mechanism may differ in
the various clinical settings and individual risk factors (Chaput and Bryson, 2012).
6.1. Neurotransmitter abnormalities
According to the neurotransmitter hypothesis, delirium is a result of complex interacting
neurotransmitter systems that modulate the control of cognition, behavior, and emotion and
pathologic processes. The decreased oxidative metabolism of the brain causes cerebral dys‐
function due to abnormalities of many neurotransmitter systems. Various symptoms and
clinical manifestations of delirium may be associated with numerous neurotransmitter activ‐
ities (van der Mast, 1998). More specifically, the pathogenesis of delirium may include the
decreased cholinergic activity; both decreased and increased serotonergic and gamma-ami‐
nobutyric acid activities and excessive release of dopamine, norepinephrine and/or gluta‐
mate (Flacker and Lipsitz, 1999).
6.2. Reduction of cerebral oxidative metabolism
Impaired oxidative metabolism is related to the development of delirium (Seaman et al.,
2006). Its dysfunction is often associated with a decrease of oxygen supply to the brain,
which leads to the widespread of cerebral dysfunction. Therefore, patients with oxygen ex‐
change dysfunction, such as cardiac diseases, intraoperative hypotension, perioperative fac‐
tors, intrinsic lung diseases and anemia may be important causes of delirium (Maldonado,
2008b, Ali et al., 2011).
6.3. Inflammatory response
Delirium is high prevalence in patients with systemic inflammatory diseases, including in‐
fection, malignancy, and the postoperative state (Marcantonio et al., 2006). Recent findings
suggest the association between cytokines and the development of delirium. Cytokine dys‐
regulation can cause neuronal injury by means of (1) abnormal neurotransmission, (2) apop‐
tosis and (3) activation of microglia and astrocytes producing free radicals, complement
factors, glutamate, and nitric oxide (Wilson et al., 2002, Simone and Tan, 2011).The cytokines
considered as proinflammatory factors (e.g., interleukin-1, interleukin-6 and interleukin-8,
tumor necrosis factor-alpha, interferon gamma and C-reactive protein) and anti-inflammato‐
ry factors (e.g., interleukin receptor antagonist and insulin-like growth factor -1) have been
hypothesized as factors related to the pathogenesis of delirium (Gunther et al., 2008, van
den Boogaard et al., 2011).
6.4. Increased activity of the hypothalamic-pituitary adrenal axis
The disturbance of hypothalamic-pituitary-adrenal (HPA) axis is another hypothesis rele‐
vant to the pathogenesis of delirium. It has been known that excessive cortisol or glucocorti‐
coid affect memory and mood in delirium (Maldonado, 2008b). The association between
delirium and disturbance of dexamethasone suppression (DST) has been noted (Robertsson
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et al., 2001). In addition, the elevation of cerebrospinal fluid (CSF) and plasma cortisol levels
observed in hip fracture patients with delirium also support the hypothesis that high brain
cortisol levels are related to delirium development (Pearson et al., 2011).
7. Management
Once delirium is diagnosed, prompt and appropriated interventions should be implement‐
ed. Other than the DSM IV-TR criteria for delirium, several measures are helpful to confirm
the diagnosis and determine the progress of illness course. Since common causes of delirium
are medical/surgical conditions and medications, priority should be given to specific treat‐
ment for the removal of these causes. Frequently, delirium is associated with multi-factorial
etiology, all possible causes, therefore, should be investigated and corrected. Because behav‐
ioral and other psychiatric disturbances are also common, psychopharmacological and psy‐
chosocial interventions are also needed in most patients. Those include the control of
behavioral disturbances, preventing complications (e.g., accident, falling) and supporting
functional needs (Burns et al., 2004).
7.1. Assessment
Physicians should review all possible contributed factors for the development of delirium,
including histories of medical/psychiatric illness, prescribed or over-the-counter medica‐
tions and substance uses. Physical examination should address in all systems, especially the
one possibly causing or contributing to the development of delirium. Mental status exami‐
nation should focus on cognitive function, such as orientation, memory, concentration, at‐
tention, language ability, mood/affect and psychotic symptoms.
The use of screening tests or tools prior to the occurrence of delirium or in patients suspect‐
ed of having delirium is very helpful for the early detection of delirium. In addition, some
measures can be used to determine the progress of delirium. Bedside cognitive screening
tests, such as the three-item registration, the three-item delayed recall test, the clock drawing
test, the problem-solving task and the ability of abstraction, can determine the cognitive im‐
pairment (de Wet et al., 2007). Example measures of delirium are the Mini-Mental State Ex‐
amination (MMSE), the original and revised versions of Delirium Rating Scale (DRS and
DRS-98), the Memorial Delirium Assessment Scale (MDAS) and the Confusion Assessment
Method (CAM) recommended (Breitbart et al., 1997, Trzepacz et al., 2001, Salawu et al.,
2009, Wongpakaran et al., 2011, Inouye et al., 1990).
To identify the causes of delirium, laboratory studies are essential. Generally, basic investi‐
gation for delirium includes a routine blood test, including complete blood count, electro‐
lytes, glucose levels, liver function test, thyroid function test, renal function test, blood
alcohol, blood ammonia, calcium/magnesium/phosphate levels, pulse oximetry, urinalysis,
urine drug screen, electrocardiogram (ECG), CSF study, radiological studies (e.g., chest x-
ray and computed tomography (CT) the head) (Salawu et al., 2009, Lorenzl et al., 2012).
However, further studies to verify infection, hypoxia and etc are also important for some pa‐
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tients. In equivocal case, electroencephalography (EEG) can be helpful. While the EEG pat‐
tern of alcohol or sedative withdrawal delirium usually presents with the prominence of
beta activity, diffuse bilateral slowing records are typical for delirium due to a general medi‐
cal condition. This later pattern of the EEG is also helpful for being used as a confirm test for
the delirious state (Jacobson and Jerrier, 2000, Salawu et al., 2009, Sidhu et al., 2009).
7.2. Specific and supportive treatment
The specific treatment for delirium is the removal of all possible causes. Therefore, the pre‐
cipitating factors must be promptly addressed and corrected (Burns et al., 2004). However,
the etiology may not be identifiable when the patient is diagnosed, sometimes cannot be
identified until the patient is recovery, and, for rare cases, cannot be identified at all. Conse‐
quently, the initially supportive and symptomatic treatments are, therefore, essential in all
patients with delirium.
7.3. Psychopharmacological treatment
7.3.1. Antipsychotics
7.3.1.1. Typical antipsychotics
To our knowledge, only two RCTs of typical antipsychotics, including haloperidol and
chlorpromazine, have been carried out.
7.3.1.1.1. Haloperidol
Haloperidol, a dopamine antagonist, has been used in various neuropsychiatric conditions.
It is considered as a first-line medication for the symptom control of delirium (American
Psychiatric Association, 1999). The advantages of this medication are that it can be adminis‐
tered through several routes. In addition, it has fewer active metabolites, less anticholinergic
effect and fewer sedative or hypotensive effects compared with other antipsychotics (Attard
et al., 2008).
Breitbart et al. (1996) conducted an RCT to compare the efficacy and safety among haloperi‐
dol, chlorpromazine and lorazepam in adult AIDS patients with delirium. Thirty patients
met the DSM-III-R criteria for delirium and scored 13 or more on the DRS. The measures
used included the DRS, the Mini-Mental State and the extrapyramidal symptoms (EPS). The
sample size was relatively small (n’s for haloperidol = 11,chlorpromazine = 13 and loraze‐
pam = 6). Based on the DRS scores, haloperidol (2.8±2.4 mg)and chlorpromazine (50±23.1
mg) were significantly superior to lorazepam for controlling the symptoms of delirium in
the first 24 hours, usually before the underlying medical causes of delirium could be identi‐
fied. The improvement of delirious symptoms was continued until the study end. The doses
of haloperidol from day 2 to the study end were decreased for an average of 1.4±1.2 mg/day.
While cognitive improvement, as measured by the Mini-Mental State, was observed as soon
as day 2 of haloperidol or chlorpromazine treatment, no cognitive improvement was found
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in the lorazepam group. At the study end, cognitive function of the haloperidol group was
significantly improved. No patient developed extrapyramidal symptoms.
Several RCTs have been conducted in comparing the efficacy and tolerability between halo‐
peridol and atypical antipsychotic medications. An RCT compared the efficacy and safety of
haloperidol and olanzapine for the treatment of delirium in the medical and surgical inten‐
sive care unit. A total of 80 delirious patients were randomized to receive either haloperidol
or olanzapine, administered orally. Measured by Delirium Index, the findings indicated that
haloperidol (a mean dose of 6.5 mg/day, range: 1–28 mg), was as effective as olanzapine (a
mean dose of 4.54 mg/day, range: 2.5–13.5 mg) in the treatment of delirium. However, the
EPS measured by Ross-Chouinard and Angus-Simpson scales was significantly more severe
in the haloperidol group (Skrobik et al., 2004).
There was a double-blind trial comparing haloperidol and risperidone for the treatment of
delirium. A total of 28 patients with delirium were enrolled and randomly assigned to re‐
ceive either a flexible-dose regimen of haloperidol or risperidone for 7 days. The measure in
efficacy is the reduction of the MDAS scores. Significant reduction of delirious symptoms
was observed in both haloperidol and risperidone groups. The average resolution times,
measured by the MDAS score of 13 or lower, were 4.22±2.48 days in the haloperidol group
and 4.17±2.14 days in the risperidone group. At the study end, the mean daily doses of the
haloperidol and the risperidone groups were 1.71±0.84 and 1.02±0.41mg, respectively. No
patient reported clinically significant side effects, except one patient in the haloperidol
group experienced mild akathisia (Han and Kim, 2004).
Grover et al. (2011) conducted an RCT to compare the efficacy and safety of haloperidol,
olanzapine and risperidone in medical and surgical in patients with delirium. A total of 64
patients (20 in the haloperidol group, 21 in the risperidone group and 23 in the olanzapine
group) participated in the study. The patients were randomly assigned to receive the flexible
dose regimens, including 0.25 to 10 mg of haloperidol, 0.25 to 4 mg of risperidone and 1.25
to 20 mg of olanzapine. The efficacy measures were the DRS-R 98 and MMSE. The mean
doses of haloperidol, olanzapine and risperidone were 0.88±0.98 mg (range: 0.25–5 mg),
3.05±1.44 mg (range: 1.25–10 mg) and 0.95±0.28 mg (range: 0.5-2 mg), respectively. Accord‐
ing to DRS-R98 and MMSE scores, haloperidol was significantly superior for the reduction
of delirious symptoms on day 6. However, the efficacy of all three regimens was not signifi‐
cantly different from other days. Four patients in a haloperidol group had some side effects.
Maneeton and colleagues conducted an RCT comparing the efficacy and tolerability be‐
tween quetiapine and haloperidol in delirious inpatients. All participants, aged 18-75 years,
were delirious patients who were consulted to a psychiatric department. The diagnoses of
all patients with DSM-IV delirium were confirmed by using the CAM. The primary efficacy
outcome was the DRS-R-98. The other efficacy measures were the Clinical Global Impres‐
sion (CGI) and hours of night sleep. The EPS was assessed by using the Modified (9-item)
Simpson-Angus Scale (MSAS). All measures were applied daily. Thirty-eight patients were
randomly to receive either a flexible dose regimen of quetiapine and haloperidol. Mean (SD)
doses of the quetiapine and haloperidol groups were 34.0±12.8 and 0.9±0.5 mg/day, respec‐
tively. Based on the DRS-R-98 and CGI scores, both haloperidol and quetiapine significantly
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reduced the symptoms of delirium from baseline to day 7. The mean hours of night-time
sleep in haloperidol and quetiapine group were 6.9±3.5 and 7.8±1.8 hours (not significantly
different). In the respect of EPS, the MSAS scores were not significantly different between
groups (Maneeton et al., 2011).
Intravenous (IV) haloperidol should be used only if the oral administration is unlikely acces‐
sible, or a rapid resolution is needed. Although some previous findings suggest the use of IV
haloperidol in these patients, most studies have low methodological quality. Two prospec‐
tive studies with small sample sizes demonstrated the efficacy of intravenous haloperidol in
disturbed behavioral control. The patients experienced a low risk of EPS (Menza et al., 1987,
Moulaert, 1989). Another prospective, controlled study of EPS in delirious patients found
that the combination of IV haloperidol and IV benzodiazepine reduced a risk of EPS com‐
pared with IV haloperidol mono therapy (Menza et al., 1988).
Although IV haloperidol appears to be effective for delirium, it should be used with great
caution. Its incidence of QT prolongation (QTP) and torsades de pointes (TdP) has been in‐
creasing reported.
Meyer-Massetti et al. (2010) summarized 54 and 42 cases with intravenous haloperidol-relat‐
ed TdP and QTP, respectively. A cumulative dose in TdP cases ranged from 5 to 645 mg,
while a that in patients with QTP alone was 2 to 1540 mg. this serious adverse event fre‐
quently occurred in the patients with concomitant risk factors. These findings suggest that a
total cumulative dose of IV haloperidol less than 2 mg appears to be safely administered. At
this cumulative dose range (<2 mg), ECG monitoring may not be needed for delirious pa‐
tients who have no concomitant risk factors.
The administration of IV haloperidol may not be possible in severe delirious and aggressive
patients. Therefore, intramuscular injection (IM) may be an alternative route for this condi‐
tion. In addition, several settings cannot routinely monitor ECG in these cases. Based on
some pharmacokinetic studies, IM haloperidol also had more rapid onset of action than that
of oral administration (Schaffer et al., 1982, Froemming et al., 1989, Wang et al., 2012).
So far, there has been promising evidence that haloperidol is effective and safe for the man‐
agement of delirium. However, a few patients may experience EPS. In the respect of effica‐
cy, haloperidol is comparable to atypical antipsychotic medications (e.g., risperidone,
olanzapine and quetiapine) but superior to lorazepam. Parenteral route for haloperidol is
widely used for the management of acute delirium. Although the IV haloperidol may rapid‐
ly control disruptive behavior of delirious patients, it also increases the incidence of TdP
and QTP. ECG monitoring may be needed for patients with concomitant risk factors or re‐
ceived a total cumulative dose of 2 mg or more for IV haloperidol. Alternatively, the admin‐
istration of IM haloperidol is effective and safe for the treatment of severe delirium.
Although it has been widely used, there has been no RCT comparing haloperidol and place‐
bo in delirious patients. Further randomized, placebo-controlled trials are useful to confirm
its efficacy and tolerability.
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7.3.1.1.2. Chlorpromazine
Chlorpromazine is the first antipsychotic drug widely used in various psychotic disorders.
The only one RCT demonstrated that it is effective for controlling delirious symptoms. Breit‐
bart et al. (1996) suggested that the low doses of chlorpromazine (50±23.1 mg) may rapidly
reduce the delirious symptoms in AIDS patients in the first 24 hours and continuously im‐
proved the symptoms until the study end. This efficacy was comparable to haloperidol but
significantly superior to lorazepam. After the first 24 hours of treatment, the average dose of
chlorpromazine from day 2 to the study end was decreased for 36±18.4 mg/day. Although
the cognitive improvement could be observed in the first two days of chlorpromazine treat‐
ment, it is slightly declined from day 2 until the treatment end. This phenomenon may be
caused by the high anticholinergic property of chlorpromazine. No patient developed clini‐
cally significant extrapyramidal symptoms.
These findings show that chlorpromazine is effective and tolerable for treating delirium.
However, due to its anticholinergic effects, cognitive function and other anticholinergic side
effects should be monitored.
7.3.1.2. Atypical antipsychotics
Although typical antipsychotic medications are the mainstay for managing behavioral dis‐
turbance in delirium, its side effects, in particular EPS and anticholinergic effects are an is‐
sue of concern. The use of atypical antipsychotic medications with less propensity to induce
EPS or cause anticholinergic effects is, therefore, an alternative. Several studies have demon‐
strated the efficacy and tolerability of atypical antipsychotic agents for controlling delirious
symptoms.
7.3.1.2.1. Risperidone
Risperidone is probable the first atypical antipsychotic agent used for controlling delirious
symptoms. An RCT comparing risperidone with haloperidol demonstrated that risperidone
is as effective as haloperidol in reducing delirious symptoms. No patient receiving risperi‐
done developed significant side effects (Han and Kim, 2004).
In a 7-day, RCT comparing the efficacy of risperidone and olanzapine in the treatment of
delirium. The outcomes included the DRS-R-98, reported adverse events and EPS. Patients
with dementia, serious hepatic problems, or bone marrow suppression, as well as those al‐
ready taking antipsychotics for behavioral problems, were excluded. Thirty-two patients,
aged 36-82 (median = 72) years, were included and randomly assigned to receive either ris‐
peridone (n = 17) or olanzapine (n = 15). Twenty-three patients had malignant cancer, and
the rest had femur fracture, head trauma, or pneumonia. The mean initial doses of risperi‐
done and olanzapine were 0.6±0.2 and 1.8±0.6 mg/day, respectively. However, the mean
doses of risperidone and olanzapine at the last observation were 0.9±0.6 and 2.4±1.7 mg/day,
orderly. With respected to the decreased DRS-R-98 scores, risperidone as well as olanzapine
were significantly superior in reducing delirious symptoms over the 7 days of study. How‐
ever, the response rates were not significantly different between groups (risperidone group:
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64.7%, olanzapine group: 73.3%). The response to risperidone was poorer in the older age
group. The median times to the recovery of delirium in the risperidone and olanzapine
groups were 5 and 3 days, respectively. Risperidone, like olanzapine, was well tolerated. Al‐
though a few patients developed extrapyramidal symptoms, they were tolerable (Kim et al.,
2010).
Another RCT conducted by Grover et al.(2011) compared the efficacy and safety of olanza‐
pine, risperidone and haloperidol in medical and surgical inpatients with delirium. The
findings indicated that risperidone, like olanzapine, was as effective as haloperidol.
Several findings support that low doses of risperidone are effective and tolerable for deliri‐
ous patients. Its efficacy is comparable to other typical and atypical antipsychotic medica‐
tions. To our knowledge, there has not been a randomized, placebo-controlled trial of
risperidone in delirious patients.
7.3.1.2.2. Quetiapine
Quetiapine is an atypical antipsychotic agent approved for the treatment of schizophrenia,
bipolar disorder and major depressive disorder. However, its evidence in controlling deliri‐
ous symptoms has been increased. There have had several RCTs conducted to determine the
efficacy and safety of quetiapine in the management of delirium.
There was a randomized, double-blind, placebo-controlled trial of quetiapine in critically ill
patients with delirium. A total of 36 delirious adult patients admitted in intensive care units
were enrolled. All patients had a score of 4 or more on the Care Delirium Screening Check‐
list, were tolerable to enteral nutrition and had no neurologic condition. The patients were
randomly assigned to receive either quetiapine 50 mg every 12 hours (n = 18) or placebo (n =
18). The doses of quetiapine were increased every 24 hours for up to 200 mg/day. The results
showed that quetiapine was superior to placebo in the respects of time to resolution of delir‐
ium, [1.0 (0.5-3.0) vs. 4.5 days (2.0-7.0), p =0.001], duration of delirium [36 (12-87) vs. 120
hours (60-195, p =0.006], and duration of agitation [6 hours (0-38) vs. 36 hours (11-66), p
=0.02)]. However, the length of hospitalization was similar in both groups (16 days vs. 16
days). The incidence of QTc prolongation and EPS were not significant different between
groups. However, somnolence was more common in the quetiapine groups (22% vs. 11%, p
=.66). In addition, the rate of discharge to home or rehabilitation was greater in the quetia‐
pine group (89% vs. 56%, p =0.06) (Devlin et al., 2010).
Tahir et al. (2010) conducted an RCT to investigate the efficacy and acceptability of quetia‐
pine for the control of delirious symptoms. Forty-two patients (21 in each group) were ran‐
domly received either quetiapine or placebo. The DRS-R-98 was used as the primary
outcome. The results demonstrated that improvement for quetiapine, as measured by DRS-
R-98 severity score, was faster than that of placebo. Based on DRS-R-98 severity score, the
quetiapine group recovered faster than the placebo group (P=0.026). In addition, the non-
cognitive items of the DRS-R-98, including restlessness, agitation, thought disorder and per‐
ceptual impairment in the quetiapine group were significantly improved faster than that of
placebo group (p=0.048).
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Lee et al. (2005) conducted an open, randomized, prospective trial to investigate the effec‐
tiveness and tolerability of quetiapine and amisulpride in delirious patients. Forty patients
with delirium were randomly assigned to receive a flexible dose of amisulpride or quetia‐
pine. Outcome measures included the DRS-R-98 and CGI-Severity (CGI-S), the total sleep
time and the quality of sleep. The mean doses of quetiapine and amisulpride were 113
mg/day and 156.4 mg/day, respectively. The DRS-R-98 scores of both groups decreased over
time. Time to recovery for the quetiapine group was 7.4±4.1 days. The quality of sleep and
the total sleep time were not significantly different between groups. Both quetiapine and
amisulpride were well tolerated.
After the reveal of promising benefits of quetiapine for delirium in an open-label study
(Maneeton et al., 2007b), Maneeton and colleagues conducted an RCT to compare the effica‐
cy and tolerability of quetiapine and haloperidol in the management of delirium. Based on
the DRS-R-98 and CGI scores, quetiapine was as effective as haloperidol in the treatment of
delirium. The mean of night time sleep was 7.8±1.8 hours for the quetiapine group. Quetia‐
pine and haloperidol were well tolerated. In addition, the incidence rates of extrapyramidal
side effects were very low in both groups (Maneeton et al., 2011).
The above mentioned findings suggest that low doses of quetiapine are effective and safe in
the treatment of delirium. Its efficacy is, at least, comparable to typical and other atypical
antipsychotic agents. Compared with other antipsychotic agents, only quetiapine has been
shown its superiority to placebo in the management of delirium. It also causes only few ad‐
verse events, including EPS and QTc prolongation, which may be comparable to placebo.
7.3.1.2.3. Olanzapine
Olanzapine is, also, an atypical antipsychotic medication approved in the treatment of schiz‐
ophrenia and bipolar disorder. There have been a few RCTs of this agent in patients with
delirium.The RCT carried out by Skrobik et al. (2004) compared the safety and efficacy of
olanzapine and haloperidol in delirious patients admitted in a critical care unit. The results
indicated that olanzapine was as effective as haloperidol in controlling delirious symptoms.
Olanzapine was a safe alternative agent, especially for delirious patients contraindicated to
haloperidol.
The study of Kim and colleagues demonstrated that olanzapine was effective for delirium.
This agent also had low incidence of adverse events, especially EPS. Its efficacy is equal to
the effects of risperidone (Kim et al., 2010).
Elsayem et al. (2010) conducted a prospective, open-label study to investigate the safety, tol‐
erability and efficacy of subcutaneous (SC) olanzapine for hyperactive or mixed delirium in
the cancer patients. The subjects had the MMSE scores of 24 or higher and agitation with
Richmond Agitation Sedation Scale (RASS) score of 1 or more. In addition, they were those
who had not responded to 10 mg or more of parenteral haloperidol over 24 hours. All sub‐
jects received olanzapine 5mg SC every eight hours for three days and continued haloperi‐
dol for controlling agitation. Twenty-four patients, aged 49 to 79, were evaluated. The
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findings indicated that the patients tolerated well with the SC olanzapine. In the respect of
agitation, only 37.5% of the subjects were rated as responders.
There was an RCT comparing the efficacy of olanzapine, risperidone and haloperidol in de‐
lirious patients. The findings suggested that olanzapine was comparable to risperidone and
haloperidol (Grover et al., 2011).
Olanzapine appears to be an effective and tolerable antipsychotic medication in the control
of delirious behavior. It can be administered in several routes, such as oral, intramuscular
and subcutaneous administration. Further well-defined studies should be conducted to con‐
firm these findings.
7.3.1.2.4. Aripriprazole
Aripiprazole is a dopamine partial agonist approved in the treatment of schizophrenia and
bipolar disorder. Similar to other antipsychotic medications, it is widely used for controlling
the behavioral disturbances and psychotic symptoms in patients with dementia and deliri‐
um. As an agent with little sedative and anticholinergic effects, it may have a few adverse
effects on attention, concentration and sleep-wake cycle. In addition, it may be beneficial for
hypoactive delirium (Straker et al., 2006). However, only a few studies of this agent have
been carried out in delirious patients.
The study of Boettger et al. (2011) compared the efficacy and tolerability between aripipra‐
zole and haloperidol for the reduction of delirious symptoms. The subjects were 21 delirious
patients treated with aripiprazole and 21 case-matched, delirious patients treated with halo‐
peridol. The measures consisted of the MDAS, the Karnofsky Performance Scale (KPS) and
the abbreviated Udvalg Kliniske Undersogelser Side Effect Rating Scale (UKU). With respect
to the MDAS, both groups improved significantly from baseline to day 7. The resolution
rates of delirium were 76.2% for both groups. Both hypoactive and hyperactive deliriums
significant improved. For those with hypoactive delirium, the rates of delirium resolution in
the aripiprazole and haloperidol groups were 100 and 77.8%, respectively. For those with
hyperactive delirium, such rates were 58.3% and 75%, respectively. However, the haloperi‐
dol group had more side effects.
Boettger and Breitbart (2011) conducted an open-label study to determine the efficacy and
safety of aripiprazole for controlling delirious symptoms in hospitalized cancer patients.
Twenty-one patients were treated with aripiprazole. Based on the changed MDAS scores,
the aripiprazole group improved significantly. The mean dose of aripiprazole was 18.3
(range 5-30) mg/day at the end of study. The rates of delirium resolution were 100% for hy‐
poactive delirium and 58.3% for hyperactive delirium. The patients with pre-morbid cogni‐
tive deficits and the hyperactive subtype of delirium did not respond well to aripiprazole
treatment. The clinically significant adverse events were not found.
The case series of Straker et al. (2006) also demonstrated the efficacy of aripiprazole in the
treatment of delirium. Fourteen patients, aged 18 to 85 and met DSM-IV-TR criteria for a di‐
agnosis of delirium, were included. The results found that 12 patients had ≥ 50 % reduction
in DSR-R-98, and 13 patients showed improvement on the CGI scores. The mean dose of ari‐
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piprazole was 8.9±3.5 mg/day. The adverse events were rare.The finding suggested that ari‐
piprazole appeared to be effective and safe in the treatment of hypoactive delirium.
The above-mentioned findings demonstrate that aripiprazole is safe and effective for deliri‐
um. As a non sedating antipsychotic agent, it may be suitable for hypoactive delirium. How‐
ever, its evidence in delirious patients is still limited.
7.3.1.2.5. Amisulpride
Amisulpride is an atypical antipsychotic agent used for the treatment of psychoses and
manic episode. Its low doses may be effective for the treatment of depression. However,
some studies have been carried out to examine its efficacy for controlling delirious symp‐
toms.
There was an RCT comparing the efficacy, tolerability and sleep quality of amisulpride and
quetiapine in controlling delirious symptoms. The findings showed that, similar to quetia‐
pine, amisulpride was safe and effective for delirious patients. The mean time to stabiliza‐
tion in the amisulpride group was 6.3±4.4 days (Lee et al., 2005). The finding suggested that
amisulpride, like quetiapine, appear to be effective and tolerable for the management of de‐
lirium. However, further studies are still needed to confirm its efficacy and safety.
Drug Treatmentroute
Resolution or
response time
(days)
Level
of
evidence*
Comments
Haloperidol Oral, IM, IV 4 Ib
IV administration increases risk of
the QT prolongation and torsades
de pointes
Chlorpromazine Oral - Ib worsen the cognitive impairment
Risperidone Oral 4-5 Ib as effective as haloperidol
Olanzapine Oral, SC 3 Ib limited efficacy in agitated deliriumfor SC administration
Quetiapine Oral 1-7 Ib effective with low risk of EPS
Amisulpride Oral 6 Ic
Aripriprazole Oral - IIIb effective in hypoactive delirium
* Gray and Taylor (2010), IM: intramuscular injection; IV: intravenous injection; SC; subcutaneous injection
Table 1. Summary of evidence on antipsychotic agents for managing delirium
7.3.2. Benzodiazepine
Lorazepam is primary used as hypnotics and anxiolytics. It has rapid onset and shorter du‐
ration of action, a low risk of accumulation and no major active metabolites. Its bioavailabili‐
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ty is predictable when it is administered either orally or intramuscularly (Attard et al., 2008).
Due to these preferable pharmacokinetic profiles, it is alternatively administered for control‐
ling disruptive behavior in several clinical settings.
There was a prospective study suggested that intravenously administration of benzodiaze‐
pine added haloperidol can reduce the risk of EPS (Menza et al., 1988). An RCT of loraze‐
pam monotherapy (3.0±3.6 mg for first 24 hours and 4.6±4.7 mg/day after day 2 ) did not
show its efficacy in controlling delirious symptoms in AIDS patients. In addition, it continu‐
ously decreased cognitive function, as measured by the MMSE. Due to these preliminary re‐
sults, this study was prematurely stopped (Breitbart et al., 1996).
Based on the results of a systematic review, there has been no adequate RCT to support the
use of benzodiazepines in the management of non-alcohol withdrawal related delirium in
patients admitted in the hospital (Lonergan et al., 2009). Although benzodiazepines are the
first-line treatment for alcoholic withdrawal delirium, their evidence in the treatment of
non-alcoholic delirium is very limited.
7.3.3. Cholinesterase inhibitors
Presumably, cholinergic deficiency (Mussi et al., 1999, Trzepacz, 2000) is postulated as neu‐
rochemical correlates of delirium. In addition, anticholinergic medications are correlated to
drug-induced delirium (Han et al., 2001), and cholinergic medications can reduce symptoms
of delirium in dementia (Wengel et al., 1998). It has been hypothesized that cholinesterase
inhibitors may be beneficial for treating cholinergic deficiency in delirium.
Overshott et al. (2010) conducted a double-blind, placebo-controlled randomized trial of ri‐
vastigmine in the management of delirious patients hospitalized in medical settings. Pa‐
tients (age≥ 65 years) were diagnosed as delirium by using the CAM. After entry, the
patients in each group were assessed by using the CAM daily. Patients with delirium were
randomly assigned to receive either rivastigmine 1.5 mg once a day and increased to 1.5 mg
twice a day after seven days or an identical placebo (two tablets after seven days). A total of
15 patients were included in the study. Eight patients received rivastigmine, and seven pa‐
tients received placebo. With regarded to the CAM scores, all patients in the rivastigmine
group and 3 patients in the placebo group had a resolution of delirium when they exited the
trial. However, there was no significant difference between groups on the duration of deliri‐
um (rivastigmine group 6.3 days versus placebo group 9.9 days).
There was an RCT comparing the efficacy and tolerability of donepezil and placebo. A total
of 80 patients were randomly assigned to orally administered donepezil 5 mg once a day or
a placebo capsule once a day, commenced 14 days before the surgery and continued taking
for 14 days following the surgery. The delirium was identified with the Delirium Symptom
Interview, the CAM, daily medical record, nurse-observation reviews, and the DSM-IV di‐
agnostic criteria for delirium. With respect to DSM-IV criteria, patients diagnosed as deliri‐
um were suggested to receive a double dose of donepezil or placebo treatments. No
measure outcome was used to assess in severity of delirium. The mean duration of postop‐
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erative delirium for the donepezil and placebo groups were 1.0 and 1.3 days, respectively
(Liptzin et al., 2005, Overshott et al., 2008).
Marcantonio et al. (2011) conducted an RCT comparing the efficacy and safety of donepezil
and placebo in reduction of the prevalence and severity of delirium in older adults undergo‐
ing hip fracture repair. Seventeen patients aged 70 or more were randomized to receive a
daily donepezil 5 mg or placebo, initiated on the day before surgery or unless possible, ad‐
ministered within 24 hours after surgery. The treatment was continued for 30 days, unless
side effects occurred. The presence and severity of delirium were measured by using the
CAM and MDAS. Patients in the donepezil group had significantly more adverse events.
With regard to delirium presence over time or the CAM scores over time, there were no sig‐
nificant differences between the donepezil and placebo groups in terms of delirium inci‐
dence or severity.
A pilot study of Oldenbeuving et al. (2008) investigated the efficacy and tolerability of riva‐
stigmine in the treatment of delirium after stroke. Seventeen patients with delirium
(DRS≥12) were treated with oral rivastigmine within the dose range of 3-12 mg a day. Based
on the DRS scores, 16 of 17 patients had a decrease in severity of delirium after rivastigmine
treatment. The mean duration of the delirium for 16 patients was 6.7 (2-17) days. No signifi‐
cant adverse event was observed.
Based on the findings, there has been no strong evidence supporting the use of cholinester‐
ase inhibitors in the treatment of delirium. Conversely, these agents may cause a greater risk
of adverse events in this population. Further studies should be carried out.
Delirious symptoms are likely to be improved by themselves after the recovery of underlin‐
ing diseases. Judgment on the severity of these behavioral symptoms is easily biased by
raters. In addition, placebo effects are noted in all area of therapeutic approach (Kradin,
2011). The percentage of placebo effect on psychiatric illness, such as anxiety and depression
is often high (Raz et al., 2011). According to the nature of this medical condition, a random‐
ized, placebo-controlled trial of a medication for controlling delirious symptoms is desper‐
ately needed to assess the efficacy and safety of a particular agent.
Among the medications mentioned above, only quetiapine has been examined in a placebo-
controlled study. The superiority of quetiapine to placebo may suggest that the agents may
be considered as first-line treatment for controlling the disruptive behavior of delirium. Low
dose of other typical and atypical antipsychotics may be also effective. The evidence so far
also suggests that haloperidol may be associated with EPS, and chlorpromazine has a risk
for anticholinergic side effects. Other atypical antipsychotics that appear to be effective and
tolerable in the management of delirium are risperidone, olanzapine, amisulpride and aripi‐
prazole. Only aripiprazole may be effective for hypoactive delirium. Although benzodiaze‐
pine, especially lorazepam, is widely used in delirium, there is no evidence supporting its
efficacy for the treatment of non-withdrawal delirium. Therefore, the use of benzodiazepine
should be limited to alcohol or benzodiazepine withdrawal delirium only. Similarly, there
has not been evidenced to demonstrate the efficacy of cholinesterase inhibitors, including
donepezil and rivastigmine, in the treatment of delirium.
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7.4. Environmental intervention
The reticular formation and its connections, the main sites of arousal and attention, are in‐
volved in delirium. Dysfunction of this system may affect the perception and interpretation
of environmental stimuli in delirious patients. The reduction or over activity of the environ‐
mental factors may exacerbate the symptoms of delirium. Several studies, especially multi‐
component programs, have supported that an environmental intervention is also effective in
the management of delirium.
Cole et al. (1994) conducted an RCT to determine a systematic intervention in elderly inpa‐
tients with DSM-IV delirium. Eighty-eight patients, aged 75 years or more, were enrolled in
the study. The patients were randomized to either the treatment group (n=42) or the control
group (n=46). Each treatment patient received a consultation by a geriatric internist or psy‐
chiatrist and followed up by a liaison nurse. Regular medical care was provided in the con‐
trol group. The environmental intervention, used in this study, was the nursing intervention
protocol, including the interventions for (1) environment: appropriate sensory input, only
one stimulus or task background stimulation at a time, and medication not interrupting
sleep, (2) orientation: environmental cues, such as clock, calendar and etc., verbal reminders
of time, place and person, and needs of eye glasses or hearing aids, (3) familiarity: familiar
possession from home, family members to stay with the patients, and the same staff to care
for them (4) communication: clear, slow paced, simple and repetitive instructions and ex‐
planations, use of face-to-face contact, a warmth attitude and kind firmness, identification
by name and information, acknowledgement of their emotions and encouragement of verbal
expression, (5) activities: avoidance in physical restraint, free movement, provision of safety,
encouragement of self-care and other personal activities. Two weeks after hospitalization, as
measured by the Short Portable Mental Status Questionnaire (SPMSQ), the improvement
was observed in the intervention group, while deterioration was observed in the control
group. However, the difference was not reported by the end of 8-week period. There were
statistically significant differences between the groups in terms of the use of restraints,
length of hospital stay, discharges to a setting providing more care than needed before ad‐
mission or mortality rate.
Milisen et al. (2001) developed and investigated the effectiveness of a nurse-led interdiscipli‐
nary intervention program for delirium. A total 120 participants (60 for intervention cohort,
60 for a usual care/non-intervention cohort) were included. The intervention protocol con‐
sisted of education for the nursing staff; systematic cognitive screening; consultative services
by a delirium resource nurse, a geriatric nurse specialist, or a psychogeriatrician; use of a
scheduled pain protocol. The findings showed that the intervention cohort group had short‐
er duration of delirium (p=0.3), less severity of delirium (p=0.049) and less memory impair‐
ment (p=0.046) than those of the control group. The length of hospital stay tended to be
decreased in the intervention cohort compared with the control (p=0.09). The study suggest‐
ed that this intervention was beneficial for older hip-fracture patients with delirium.
Cole et al. (2002) conducted an RCT to investigate the effectiveness of systematic detection
and multidisciplinary care of delirium in reducing time to improvement of cognitive status
in older patients admitted to general medical settings. Two hundred twenty-seven patients
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with high prevalent or incident delirium participated in the study. Significant differences
between groups were not observed within the eight weeks after enrolment in terms of time
to and rate of improvement of the Delirium Index, the Barthel Index, length of stay, rate of
discharge into the community, living arrangements after discharge or survival. Based on the
findings, systematic detection and multidisciplinary care of delirium did nots how a benefit
over usual care for elderly patients in medical settings.
A prospective intervention study conducted by Lundstrom et al. (2005) determine an educa‐
tion program and a reorganization of nursing and medical care for improving the symptoms
of delirium in elderly patients. A total of 400 patients, aged 70 or older, were consecutively
admitted to either an intervention or a control ward. The intervention program composed of
staff education emphasizing on the assessment, prevention, and treatment of delirium, as
well as caregiver-patient interaction. The Organic Brain Syndrome Scale and the MMSE
were used as outcome measures. Fewer patients in the intervention ward had delirious
symptoms on day 7 compared with the control group (30.2% vs 59.7%, p=0.001). The mean
length of hospitalization was significantly shorter in the intervention patients as compared
with the control ones (9.4±8.2 vs 13.4±12.3 days, P< 0.001), especially for the delirious pa‐
tients (10.8±8.3 vs 20.5±17.2 days, P< 0.001).
Inouye et al. (2006) conducted a cross-sectional survey of the Hospital Elder Life Program
(HELP) dissemination in 17 study sites. The trained interdisciplinary teams assessed and in‐
tervened on six delirium risk factors, including orientation, therapeutic activities, early mo‐
bilization, vision/hearing optimization, oral volume repletion and sleep enhancement. The
finding that the HELP improved hospital outcomes in delirium was promising in this popu‐
lation.
There was a prospective analysis to determine the pattern and frequency of implementation
of environmental intervention in managing delirious patients admitted in an acute hospital
service. Forty-six patients meeting the ICD-10 criteria for delirium were studied. The pa‐
tients were categorized into hyperactive, hypoactive or mixed subtypes of delirium. The en‐
vironmental strategies were the eight basic nursing strategies for delirium, including (1)
frequent observation; (2) efforts by staff to re-orientate the patient to the surroundings; (3)
effort made to avoid excessive staff changes; (4) nurse in single room; (5) uncluttered nurs‐
ing environment; (6) use of an individual night light; (7) specific effort to minimize noise
levels and (8) relatives or friends specifically requested to visit regularly in an effort to en‐
hance re-orientation. The study found that these environmental strategies were more benefi‐
cial in the management of behavioral difficulties, such as overall severity of delirium,
agitation, mood lability and sleep-wake cycle disturbance, than the core features of deliri‐
um, such as severity of disorientation, disturbed perception/thinking (Meagher et al., 1996).
The above-mentioned studies suggest the benefits ofthe environmental interventions for de‐
lirium, and, therefore, should be recommended in all patients with delirium. Those inter‐
ventions aim to correct or reduce the sensory impairment, and to improve the patient’s
perception, by using eyeglasses and hearing aids. Optimal sensory stimulation is helpful to
decrease the behavioral disturbance of delirium. While sensory deprivation may exacerba‐
tethe behavioral disturbance, over stimulation, such as loud noise, should be also avoided.
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Providing environmental cues, such as calendar, clock, family pictures, windows, should be
encouraged to facilitate orientation. In addition, supportive interventions, including re-ori‐
entation, reassurance and explanation about delirium, could reduce fear and anxiety.
8. Prevention
Once a patient with high risks of delirium is hospitalized, all risks should be addressed, fol‐
lowed by the employment of effective preventive strategies (Salawu et al., 2009). Some stud‐
ies have shown the benefits of some preventive interventions for delirium. In general, those
strategies usually include the multidisciplinary and psychopharmacological interventions.
8.1. Non-pharmacological interventions
Multi-factors, including patient vulnerabilities, predisposing factors at admission and pre‐
cipitating factors during hospitalization can interactively cause syndrome of delirium.
Inouye (2000) conducted a controlled clinical trial in 852 subjects to prevent delirium in eld‐
erly inpatients. Significant predisposing factors for delirium included vision impairment, se‐
vere illness, cognitive impairment and dehydration. Precipitating factors were physical
restraint use, malnutrition, adding more than three drugs, bladder catheter use, and any ia‐
trogenic event. The findings showed that the incidence of delirium was significantly re‐
duced in the intervention group compared with usual care (9.9% vs. 15.0%, 95% CI:
0.39-0.92). The total number of days and episodes of delirium were also significantly smaller
in the intervention group. These findings suggested that delirium prevention is useful and
could reduce the morbidity and mortality associated with delirium in elderly patients.
Colombo  et  al.  (2012)  conducted  a  two-stage  prospective  observational  study  to  deter‐
mine the epidemiology, risk factors and predictors of delirium. The subjects were all pa‐
tients  admitted  to  the  ICU  settings  over  a  year.  The  first  phase  was  the  observational
stage, while the second one was the interventional phase. Delirium assessment was per‐
formed by using of the CAM twice daily after the sedation interruption. For the second
phase, the patients were received both a re-orientation and environmental manipulations
(e.g.,  acoustic  and visual  stimulation).  The patients in phase 1 and 2 were 170 and 144,
respectively.  The incidence rate of delirium was significantly lower in the interventional
group (phase-I  vs.  phase-II:  22% vs.  35.5%,  p  =  0.020).  Based on the  Cox's  Proportional
Hazard  model,  the  use  of  re-orientation  strategy  was  the  strongest  protective  factor  of
delirium:  (HR  0.504,  95%  C.I.  0.313-0.890,  p=0.034),  while  age  (HR  1.034,  95%  CI:
1.013-1.056,  p=0.001)  and  sedation  with  midazolam  plus  opiate  (HR  2.145,  95%  CI:
2.247-4.032, p=0.018) were negative predictors.
Milisen et al. (2001) conducted a systemic review to investigate the characteristics and effica‐
cy of various multicomponent programs for managing older patients with delirium admit‐
ted in hospitals. Three RCTs, three controlled trials and one before-after study were
included in the review. The multicomponent strategies for preventing delirium appear to be
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the most efficacious in reducing the incidence, both in surgical and medical patients. In ad‐
dition, some additional effects of preventive intervention were observed in the duration and
severity of delirium, as well as functional status. The review suggested that multicomponent
strategies are effective for preventing delirium.
Yang et al. (2008) conducted a prospective cohort study to investigate the mediating role of
activity participation between educational attainment and risk of delirium. The contribu‐
tions of participation in specific activities for the development of delirium were also deter‐
mined. Seven hundred seventy-nine newly admitted patients without dementia, aged 70 or
older, were studied. The findings showed that activity participation before hospitalization
mediated the relationship between education and risk for delirium in elderly persons with‐
out dementia. It also suggested that participation in regular exercise was a significantly pro‐
tective factor of delirium.
Another study examined the efficacy of multicomponent intervention for preventing deliri‐
um. Inpatients with an intermediate or high risk for delirium were randomly assigned to re‐
ceive either a non-pharmacological intervention delivered by family members (144 patients)
or standard management (143 patients). The outcome measure was the occurrence of deliri‐
um during hospitalization. The incidence rates of delirium in the intervention group and the
control group were 5.6% and 13.3% (relative risk:0.41; 95% CI: 0.19–0.92; P = 0.027), respec‐
tively. The findings suggested that the non-pharmacological prevention of delirium given
by family members, as compared with standard management, could reduce the patients'
risk of delirium (Martinez et al., 2012).
These findings suggest that non-pharmacological interventions can reduce the incidence of
delirium. Effective interventions, including multicomponent approach frequently focuses on
predisposing factors in an individual patient. However, environmental prevention, such as
re-orientation and environmental stimulation, are also effective for preventing delirium. A
strong protective factor against delirium is the routinely participation in exercise. The use of
multicomponent interventions by family members can also reduce the risk of delirium.
8.2. Psychopharmacological interventions
There have been several studies examining the effectiveness of antipsychotic medications
for  preventing delirium.  Kalisvaart  et  al.  (2005)  conducted an RCT comparing haloperi‐
dol  and  placebo  for  preventing  postoperative  delirium  in  elderly  hip-surgery  patients,
who were at risk for delirium. A number of 430 hip-surgery patients, aged 70 and older,
at  risk  for  postoperative  delirium  were  randomly  assigned  to  receive  haloperidol  1.5
mg/d  or  placebo,  started  before  surgery  and  continued  for  up  to  3  days  after  surgery.
The incidence rates  of  postoperative delirium in both groups were not  significantly dif‐
ferent (haloperidol vs placebo, 15.1% vs. 16.5%). The means of delirium duration in halo‐
peridol  and  placebo  treatment  groups  were  5.4  vs  11.8  days,  orderly  (mean  difference
4.0, 95% CI=2.0-5.8, P<.001), and the means of hospital stay were 17.1±11.1 and 22.6±16.7
days, respectively (mean difference 5.5 days, 95% CI=1.4-2.3; P<.001). The adverse events
were not  significantly different  between groups.  These results  suggested that  low doses
of  haloperidol  might  not  be  able  to  prevent  postoperative  delirium.  However,  it  is  safe
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and can  decrease  the  severity,  duration,  and the  length  of  hospitalization  for  these  pa‐
tients.
Wang et al. (2012) conducted an RCT to determine the efficacy and safety of intravenous
haloperidol for preventing delirium in critically ill elderly patients who had undergone non‐
cardiac surgery. A total of 457 patients, aged 65 years older, who were admitted to the inten‐
sive care unit after non cardiac surgery, were included and randomized to receive either
haloperidol (0.5 mg intravenous bolus injection followed by continuous infusion at a rate of
0.1 mg/h for 12 hours; n = 229) or placebo (n = 228). The incidence rates of delirium were
significantly lower in the haloperidol group(15.3% vs 23.2%, p = 0.031) during the first seven
day after surgery. No drug related adverse event was noted. A short-term, low-dose intrave‐
nous haloperidol prophylaxis appeared to reduce the incidence rate of postoperative deliri‐
um.
Prakanrattana and Prapaitrakool (2007) conducted an RCT to determine the effects of risper‐
idone in preventing postoperative delirium after cardiac surgery with cardiopulmonary by‐
pass. A total of 126 adult patients underwent elective surgery were randomized to receive
risperidone 1 mg or placebo after regained consciousness. With regard to the using of CAM,
the incidence of postoperative delirium in the risperidone group was significantly lower
than that in the placebo group (11.1% vs. 31.7% respectively, P=0.009, relative risk: 0.35, 95%
CI: 0.16-0.77).
Larsen et al. (2010) conducted an RCT comparing the efficacy of olanzapine and placebo in
preventing postoperative delirium in elderly patients after joint-replacement surgery. A to‐
tal of 400 elderly patients, aged 65 years or more, who had undergone elective knee- or hip-
replacement surgery, were randomly assigned to receive either 5 mg of orally-disintegrating
olanzapine or placebo before and after surgery. The findings showed that the olanzapine
group had a significantly lower incidence of delirium.
There have been a few studies of cholinesterase inhibitors for preventing delirium. Liptzin
et al. (2005) conducted an RCT comparing donepezil and placebo for the prophylaxis of
postoperative delirium in elderly patients, who had undergone elective total joint-replace‐
ment surgery. Eighty patients without dementia were randomly assigned to receive either
donepezil or placebo for 14 days before surgery and 14 days afterward. The findings did not
show any benefit of donepezil in preventiong delirium in this population.
Gamberini et al.  (2009) conducted an RCT to compare rivastigmine and placebo for pre‐
venting  delirium in  elderly  patients  during  the  first  six  days  after  elective  cardiac  sur‐
gery.  A  total  of  120  patients,  aged  65  or  older,  underwent  the  surgery  with
cardiopulmonary bypass were randomized to receive either placebo or rivastigmine. The
incidence rates of delirium were not significantly between groups (30% vs 32%, p = 0.8).
The  findings  did  not  support  a  short-term  oral  administered  rivastigmine  for  delirium
prophylaxis in this population.
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Drug Routeadministration Dose
Level
of
evidence*
Comment
Haloperidol IV 0.1 mg/hr 1b
0.5 mg intravenous bolus injection
followed by continuous infusion at a rate of
0.1 mg/h for 12 hrs
Risperidone Oral 1 mg/day 1b
Olanzapine Oral 5 mg/day 1b
Melatonin Oral 0.5 mg/day 1b Administer at night
* Gray and Taylor (2010)
Table 2. Summary of evidences relevant to the pharmacological prophylaxis of delirium
There was a randomized, double-blinded, placebo-controlled trial of low dose exogenous
melatonin in preventing delirium. A total of 145 patients, aged 65 years or older, hospital‐
ized in a medical unit were randomly assigned to receive either 0.5 mg of melatonin or pla‐
cebo every night for 14 days or until discharge. Based on the CAM, the incidence rate of
delirium in the melatonin group was significant lower than that in the placebo group (12%
vs 31%, p=0.014). The findings suggested that exogenous low dose melatonin may be of ben‐
efit in preventing delirium in this population (Al-Aama et al., 2012).
The above-mentioned findings demonstrate the benefits low-dose risperidone and olanza‐
pine in preventing delirium. While they can reduce the incidence rate of delirium, their ad‐
verse events, in particular EPS, appear to be comparable to placebo. Similarly, exogenous
low-dose melatonin administered at night time may be able to prevent delirium. Although
haloperidol can reduce severity, duration and length of hospital stay in postoperative deliri‐
um, it might not be able to prevent the occurrence of this condition. However, cholinesterase
inhibitors, including donepezil and rivastigmine may have no efficacy in this regard. There‐
fore, at low doses, high-potency antipsychotic agents, atypical antipsychotic medications or
exogenous melatonin may be beneficial for the prevention of delirium in patients at high
risk or subsydrome of delirium.
9. Further studies
Several lines of evidence indicate that pharmacological and environmental interventions are
effective in the management and prophylaxis of delirium. However, those studies still have
some limitations, including methodological weakness, small sample sizes, lack of placebo
control in several studies and the specific patients. Further randomized, placebo-controlled
trials and systemic reviews with well-defined methodology, large sample sizes, consistent
outcomes and various clinical settings may be helpful in clarifying the benefits of these in‐
terventions.
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10. Conclusion
Delirium is a condition in medical emergency, common in medical or surgical settings and
highly incident in intensive care units. Several causative factors for the development of de‐
lirium have been identified. Specific treatment for curing or removing the causes is an effec‐
tive approach. Initially, the precipitating factors are often overlooked or unidentified.
Therefore, supportive and symptomatic managements are beneficial. For hyperactive type
of delirium, all antipsychotic medications may help relief the behavioral disturbance, in‐
cluding psychotic symptoms. Although haloperidol is considered as the first-line treatment,
it may increase the risk of adverse events, especially EPS. Alternatively, atypical antipsy‐
chotic agents, which have low propensity to induce EPS, may be useful in this condition. In‐
travenous haloperidol may be associated with QT prolongation and torsades de pointes. To
avoid these serious adverse events, only low doses of IV haloperidol (a total cumulative
dose < 2 mg) should be administered in delirious patients without concomitant risk factors.
Based on its pharmacokinetic profile, IM haloperidol can be an alternative for the behavioral
control of acute or severe delirium. For hypoactive delirium, only aripriprazole, a non seda‐
tive antipsychotic agent, is evidently beneficial. In addition to psychopharmacological inter‐
ventions, environmental manipulation is also necessary in the management of delirium and
should be used in all delirious patients. Preventing delirium is challenging. A number of
studies demonstrate the efficacy of some interventions in preventing delirium. The multi‐
component strategy, systemically focusing on predisposing factors in individual patients is
one of the highly effective approaches. Pharmacological prophylaxis is another strategy in
preventing delirium. The evidence so far suggests that risperidone, olanzapine and melato‐
nin may be effective in preventing delirium.
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